#hourly #fox https://api.tinyfox.dev/hourly/HourlyFoxes/FcRN-BDXkAAw3kS.jpg
August 1, 2025 at 7:00 AM
#hourly #fox https://api.tinyfox.dev/hourly/HourlyFoxes/FcRN-BDXkAAw3kS.jpg
THE FIRST FDA-APPROVED TREATMENT FOR MY RARE DISEASE IS HERE 😭😭😭 BRO I CANNOT BELIEVE THIS DAY IS HERE 😭😭😭
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
· IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function · Warm autoimmune hemolytic anemia is a...
www.jnj.com
August 24, 2026 at 11:46 PM
THE FIRST FDA-APPROVED TREATMENT FOR MY RARE DISEASE IS HERE 😭😭😭 BRO I CANNOT BELIEVE THIS DAY IS HERE 😭😭😭
Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. Learn more in a new review: nej.md/42gEZYk
#MedSky #GastroSky
#MedSky #GastroSky
April 30, 2025 at 1:27 PM
Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. Learn more in a new review: nej.md/42gEZYk
#MedSky #GastroSky
#MedSky #GastroSky
for IgG mediated diseases, this means that FcRn also recycles pathogenic IgG autoantibodies, which perpetuates disease. so targeting FcRn can reduce circulation of IgG autoantibodies and reduce disease symptoms.
February 27, 2024 at 4:37 PM
for IgG mediated diseases, this means that FcRn also recycles pathogenic IgG autoantibodies, which perpetuates disease. so targeting FcRn can reduce circulation of IgG autoantibodies and reduce disease symptoms.
I am a big FcRn believer! I worked on an FcRn inhibitor, and I constantly tell them that mechanistically, I think this strategy will be incredible for WAHA
February 27, 2024 at 4:27 PM
I am a big FcRn believer! I worked on an FcRn inhibitor, and I constantly tell them that mechanistically, I think this strategy will be incredible for WAHA
the neonatal Fc receptor (FcRn) plays a key role in recycling IgG antibodies. basically, FcRn binds to IgG so that they don’t go to the lysosome where they are destroyed. this allows bound IgG to re-enter circulation.
February 27, 2024 at 4:37 PM
the neonatal Fc receptor (FcRn) plays a key role in recycling IgG antibodies. basically, FcRn binds to IgG so that they don’t go to the lysosome where they are destroyed. this allows bound IgG to re-enter circulation.
Most vaccines don’t trigger mucosal IgA—a key airway defense
Clever new Nat Comm study from 🇳🇴 solves that by fusing antigens to albumin, which uses FcRn pathway to cross the nasal barrier
Result: a potent intranasal vaccine that protects vs. both flu and SARS-CoV-2
www.nature.com/articles/s41...
Clever new Nat Comm study from 🇳🇴 solves that by fusing antigens to albumin, which uses FcRn pathway to cross the nasal barrier
Result: a potent intranasal vaccine that protects vs. both flu and SARS-CoV-2
www.nature.com/articles/s41...
May 2, 2025 at 3:52 AM
Most vaccines don’t trigger mucosal IgA—a key airway defense
Clever new Nat Comm study from 🇳🇴 solves that by fusing antigens to albumin, which uses FcRn pathway to cross the nasal barrier
Result: a potent intranasal vaccine that protects vs. both flu and SARS-CoV-2
www.nature.com/articles/s41...
Clever new Nat Comm study from 🇳🇴 solves that by fusing antigens to albumin, which uses FcRn pathway to cross the nasal barrier
Result: a potent intranasal vaccine that protects vs. both flu and SARS-CoV-2
www.nature.com/articles/s41...
Next, what this study shows us is that although SOME patients may have autoantibodies driving symptoms, it is not all patients. This may explain why some trials of FcRn inhibitors failed: because it was hard to phenotype and immunophenotype the patients, many people with LC
6/
6/
May 28, 2026 at 7:00 PM
Next, what this study shows us is that although SOME patients may have autoantibodies driving symptoms, it is not all patients. This may explain why some trials of FcRn inhibitors failed: because it was hard to phenotype and immunophenotype the patients, many people with LC
6/
6/
FcRn-regulated cellular pathways are involved in tissue responses that are associated with autoimmune diseases, as shown in models of inflammatory bowel disease and rheumatoid arthritis, or immune responses to cancer. Learn more in a new review: nej.md/42gEZYk
#MedSky #GastroSky
#MedSky #GastroSky
April 28, 2025 at 5:04 PM
FcRn-regulated cellular pathways are involved in tissue responses that are associated with autoimmune diseases, as shown in models of inflammatory bowel disease and rheumatoid arthritis, or immune responses to cancer. Learn more in a new review: nej.md/42gEZYk
#MedSky #GastroSky
#MedSky #GastroSky
hope to learn: do we see these issues in similar proportions in folks with pre-2020 #MECFS diagnoses? Or chronic #lyme? How can we use these findings to reimagine trials of IVIG and/or FcRn inhibitors for #LongCOVID. Finally, although this work validates autoimmunity as a
8/
8/
May 28, 2026 at 7:00 PM
hope to learn: do we see these issues in similar proportions in folks with pre-2020 #MECFS diagnoses? Or chronic #lyme? How can we use these findings to reimagine trials of IVIG and/or FcRn inhibitors for #LongCOVID. Finally, although this work validates autoimmunity as a
8/
8/
FcRn protects IgG and albumin from catabolism, transports IgG across the placenta, and regulates IgG function. Blocking or augmenting FcRn can decrease autoimmune antibodies and enhance drug delivery. Learn more in a new Review Article: nej.md/42gEZYk
#MedSky
#MedSky
April 23, 2025 at 9:59 PM
FcRn protects IgG and albumin from catabolism, transports IgG across the placenta, and regulates IgG function. Blocking or augmenting FcRn can decrease autoimmune antibodies and enhance drug delivery. Learn more in a new Review Article: nej.md/42gEZYk
#MedSky
#MedSky
FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology
@Cell_Metabolism
www.cell.com/cell-metabol...
@Cell_Metabolism
www.cell.com/cell-metabol...
December 17, 2024 at 5:47 PM
FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology
@Cell_Metabolism
www.cell.com/cell-metabol...
@Cell_Metabolism
www.cell.com/cell-metabol...
This is some of the most exciting observational research into post-viral illness. At the end, @virusesimmunity.bsky.social says that positive results would lead them to try to pursue trials with immunotherapies like FcRn inhibitors, B cell targeting therapies, and IVIg.
Solve ME: 'Probing Functional Autoantibodies in Patients with ME/CFS'
'Dr. Akiko Iwasaki (Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University) is the first recipient of Solve’s ME/CFS Catalyst Award..'
www.youtube.com/watch?v=9ar0...
'Dr. Akiko Iwasaki (Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University) is the first recipient of Solve’s ME/CFS Catalyst Award..'
www.youtube.com/watch?v=9ar0...
Probing Functional Autoantibodies in Patients with ME/CFS
YouTube video by SolveME
www.youtube.com
August 1, 2025 at 4:51 PM
This is some of the most exciting observational research into post-viral illness. At the end, @virusesimmunity.bsky.social says that positive results would lead them to try to pursue trials with immunotherapies like FcRn inhibitors, B cell targeting therapies, and IVIg.
The neonatal Fc receptor (FcRn): Guardian or Trojan Horse in viral infection?
journals.plos.org/plospathogen...
journals.plos.org/plospathogen...
The neonatal Fc receptor (FcRn): Guardian or Trojan Horse in viral infection?
The neonatal Fc receptor (FcRn), well-known for mediating the transfer of maternal immunoglobulin G (IgG) to neonates, plays a critical role in neonatal antimicrobial defenses. Furthermore, FcRn regul...
journals.plos.org
July 8, 2025 at 1:07 PM
The neonatal Fc receptor (FcRn): Guardian or Trojan Horse in viral infection?
journals.plos.org/plospathogen...
journals.plos.org/plospathogen...
The neonatal FcRn receptor, which persists in adult life, can be exploited both ways. In a Br J Haematology paper, its inhibition is exploited as a treatment of #ITP. In congenital #hemophilia, it is used to enhance the half-life of FVIII and FIX. tinyurl.com/c46hm9nv
November 20, 2024 at 10:46 AM
The neonatal FcRn receptor, which persists in adult life, can be exploited both ways. In a Br J Haematology paper, its inhibition is exploited as a treatment of #ITP. In congenital #hemophilia, it is used to enhance the half-life of FVIII and FIX. tinyurl.com/c46hm9nv
Handy dandy visual of current and targeted therapies. Anti-FcRn therapy (SYNT001) on the upper far right.
Taken from:
www.sciencedirect.com/science/arti...
Taken from:
www.sciencedirect.com/science/arti...
February 27, 2024 at 4:43 PM
Handy dandy visual of current and targeted therapies. Anti-FcRn therapy (SYNT001) on the upper far right.
Taken from:
www.sciencedirect.com/science/arti...
Taken from:
www.sciencedirect.com/science/arti...
The unique pharmacology of targeted degraders (eg PROTACs) leverages their sub-stoichiometric “catalytic” activity. Now Lycia Tx reports catalytic (cata)LYTACs for potent, durable extracellular #TPD, cleared IgE in NHPs, superior to omalizumab 👏
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACs
Circulating proteins are common targets for the discovery of occupancy-based inhibitors including monoclonal antibodies. Effective inhibition of target pathogenicity with blocking approaches, however,...
www.biorxiv.org
January 13, 2025 at 4:29 PM
The unique pharmacology of targeted degraders (eg PROTACs) leverages their sub-stoichiometric “catalytic” activity. Now Lycia Tx reports catalytic (cata)LYTACs for potent, durable extracellular #TPD, cleared IgE in NHPs, superior to omalizumab 👏
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
2) Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). This receptor normally protects antibodies from breakdown, so blocking it leads to a reduction in antibodies.
The drug is already approved as a treatment for myasthenia gravis.
The drug is already approved as a treatment for myasthenia gravis.
September 20, 2026 at 7:28 AM
2) Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). This receptor normally protects antibodies from breakdown, so blocking it leads to a reduction in antibodies.
The drug is already approved as a treatment for myasthenia gravis.
The drug is already approved as a treatment for myasthenia gravis.
"The neonatal Fc receptor is a cellular receptor for human astrovirus"
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The neonatal Fc receptor is a cellular receptor for human astrovirus - Nature Microbiology
A CRISPR-based screen identifies neonatal Fc receptor (FcRn) and dipeptidyl-peptidase IV (DPP4) as entry factors for human astrovirus, and targeting them using available therapies effectively prevents...
www.nature.com
December 12, 2024 at 6:44 AM
"The neonatal Fc receptor is a cellular receptor for human astrovirus"
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Wow! Yu et al. reveal that IgG accumulates in obese adipose tissue via FcRn recycling in macrophages and adipocyte progenitor cells. Disrupting FcRn reverses metabolic dysfunction, offering a novel obesity intervention path. 🧪 www.sciencedirect.com/science/arti... @cp-cellmetabolism.bsky.social
December 19, 2024 at 10:30 AM
Wow! Yu et al. reveal that IgG accumulates in obese adipose tissue via FcRn recycling in macrophages and adipocyte progenitor cells. Disrupting FcRn reverses metabolic dysfunction, offering a novel obesity intervention path. 🧪 www.sciencedirect.com/science/arti... @cp-cellmetabolism.bsky.social
This opens the door to new treatment strategies:
If antibodies are causal, therapies that target them might help patients:
• immunoadsorption → which we are already testing @amsterdamumc.bsky.social : www.youtube.com/watch?v=fE7A...
• FcRn targeting
• Plasma cell–targeting therapies 10/12
If antibodies are causal, therapies that target them might help patients:
• immunoadsorption → which we are already testing @amsterdamumc.bsky.social : www.youtube.com/watch?v=fE7A...
• FcRn targeting
• Plasma cell–targeting therapies 10/12
Amsterdam UMC Long-COVID clinical trial immunoadsorption
YouTube video by Jeroen den Dunnen
www.youtube.com
March 24, 2026 at 4:05 PM
This opens the door to new treatment strategies:
If antibodies are causal, therapies that target them might help patients:
• immunoadsorption → which we are already testing @amsterdamumc.bsky.social : www.youtube.com/watch?v=fE7A...
• FcRn targeting
• Plasma cell–targeting therapies 10/12
If antibodies are causal, therapies that target them might help patients:
• immunoadsorption → which we are already testing @amsterdamumc.bsky.social : www.youtube.com/watch?v=fE7A...
• FcRn targeting
• Plasma cell–targeting therapies 10/12
If you were a participant in the Vyvgart trial, please email Mackenzie at coreresearch@mountsinai.org to get a free at-home lab kit.
Mt. Sinai & Yale are testing against a newly discovered autoimmune biomarker, with the goal of initiating a new FCRN inhibitor trial by year-end!
Mt. Sinai & Yale are testing against a newly discovered autoimmune biomarker, with the goal of initiating a new FCRN inhibitor trial by year-end!
July 13, 2026 at 8:19 PM
If you were a participant in the Vyvgart trial, please email Mackenzie at coreresearch@mountsinai.org to get a free at-home lab kit.
Mt. Sinai & Yale are testing against a newly discovered autoimmune biomarker, with the goal of initiating a new FCRN inhibitor trial by year-end!
Mt. Sinai & Yale are testing against a newly discovered autoimmune biomarker, with the goal of initiating a new FCRN inhibitor trial by year-end!
US20260274961A1 discloses dual-variable-domain IgGs targeting FcRn and activating FcγR to redirect immune-complex handling. FcRn/FCGR2A knockout and transgenic models, including K/B×N arthritis, test receptor dependence. Key risk: immune-complex clearance may amplify myeloid inflammation.
September 27, 2026 at 1:02 PM
US20260274961A1 discloses dual-variable-domain IgGs targeting FcRn and activating FcγR to redirect immune-complex handling. FcRn/FCGR2A knockout and transgenic models, including K/B×N arthritis, test receptor dependence. Key risk: immune-complex clearance may amplify myeloid inflammation.
#EcksteinsMonthOfMusic
#MusicChallenge
Day 13
A song about getting away with something:
Steal Away - Nils Lofgren
From the 1979 album, Nils
m.youtube.com/watch?v=fcRN...
#MusicChallenge
Day 13
A song about getting away with something:
Steal Away - Nils Lofgren
From the 1979 album, Nils
m.youtube.com/watch?v=fcRN...
Steal Away
YouTube video by Nils Lofgren - Topic
m.youtube.com
June 13, 2026 at 4:41 PM
#EcksteinsMonthOfMusic
#MusicChallenge
Day 13
A song about getting away with something:
Steal Away - Nils Lofgren
From the 1979 album, Nils
m.youtube.com/watch?v=fcRN...
#MusicChallenge
Day 13
A song about getting away with something:
Steal Away - Nils Lofgren
From the 1979 album, Nils
m.youtube.com/watch?v=fcRN...
A new #ScienceImmunology study highlights the limitations of preclinical models for human antibody-based drugs, and demonstrates how a humanized mouse model may improve study outcomes. https://scim.ag/4t2ye7T
Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling
Preclinical modeling of human IgG–based drugs is enhanced through humanized Fcγ receptor and FcRn expression in a murine knockin model.
scim.ag
February 3, 2026 at 4:14 PM
A new #ScienceImmunology study highlights the limitations of preclinical models for human antibody-based drugs, and demonstrates how a humanized mouse model may improve study outcomes. https://scim.ag/4t2ye7T